European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

July 30, 2018 KEYTRUDA Combination Improved Overall Survival Compared with Pemetrexed and Platinum Chemotherapy Alone in Pivotal Phase 3 Trial (KEYNOTE-189) Positive Opinion for KEYTRUDA Also Adopted for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-040)

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

19 July 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced

Lilly’s Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease

Lilly’s Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease

July 19, 2018 Lilly’s Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease INDIANAPOLIS, July 19, 2018 /PRNewswire/ — The U.S. label for Eli Lilly and Company’s (NYSE: LLY) once-weekly

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

July 13, 2018 First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

July 12, 2018 BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics

Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and…

Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and…

July 11, 2018 Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low-Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan In the CheckMate -142 trial, Opdivo +

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

Jul 10, 2018 First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic triple negative breast cancer (TNBC)  IMpassion130 is the third positive Phase III study to demonstrate a clinical benefit with the investigational combination

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

02 July 2018 Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Second approval in Japan for AstraZeneca and MSD’s Lynparza AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

02 July 2018 Imfinzi is the only immunotherapy approved for unresectable Stage III NSCLC Approval is based on the Phase III PACIFIC trial AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of

GenomeDx Announces Cigna Coverage for Decipher Prostate Cancer Tests

GenomeDx Announces Cigna Coverage for Decipher Prostate Cancer Tests

June 21, 2018 — Decipher obtains positive coverage decisions for both the biopsy and post-surgical prostate settings — SAN DIEGO, June 21, 2018 /PRNewswire/ — GenomeDx Biosciences, a leader in the field of urologic cancer genomics, announced today that Cigna® issued positive medical

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

June 21, 2018 Life Science Incubator Selects New QuickFire Challenge Winners to Join JLABS @ NYC NEW YORK, June 21, 2018 /PRNewswire/ — Johnson & Johnson Innovation LLC today announced the opening of JLABS @ NYC. The 30,000-square foot facility, located at the New

Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

June 21, 2018 NEW YORK, June 21, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S. for its

Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC

Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC

June 21, 2018 Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC) SAN DIEGO, June 21,

Hygieia Signs Commercial Agreement Making d-Nav® Insulin Guidance Service Available to At-Risk Blue Cross Blue Shield of Michigan Members in Southeast Michigan

Hygieia Signs Commercial Agreement Making d-Nav® Insulin Guidance Service Available to At-Risk Blue Cross Blue Shield of Michigan Members in Southeast Michigan

June 21, 2018 — First U.S. commercial contract demonstrates potential for Service to improve standard of care for large Type 2 diabetes population — LIVONIA, Mich., June 21, 2018 /PRNewswire/ — Hygieia, a digital insulin enhancement company dedicated to making insulin therapy easier

Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study

Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study

June 21, 2018 Leveraging ADAPT Biotargeting System would have significantly increased the probability of success Data presented at the ESMO World Congress on Gastrointestinal Cancer 2018 IRVING, Texas, June 21, 2018 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on

Nature Study Leverages Artificial Intelligence to Reveal Never-before-seen Cage Structure of Ultra-small Particles

Nature Study Leverages Artificial Intelligence to Reveal Never-before-seen Cage Structure of Ultra-small Particles

June 20, 2018 These New Findings Support Benefits of Elucida’s C-Dot Technology and Pave the Way for Applications in Medicine, Catalysis, Energy, Optics and Other Areas NEW YORK, June 20, 2018 /PRNewswire/ — Elucida Oncology, a biotechnology company developing a first-in-class nanotechnology platform,

Stratus Pharmaceuticals Announces Results Of FDA Inspection To Stratus’s Distribution Center

Stratus Pharmaceuticals Announces Results Of FDA Inspection To Stratus’s Distribution Center

June 20, 2018 MIAMI, June 20, 2018 /PRNewswire/ — Stratus Pharmaceuticals has received correspondence from the FDA indicating the Establishment Inspection Report (EIR) results of the inspection that took place during 03/06/2018 to 03/08/2018 , showing that there were no 483 Items and as

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

June 20, 2018 Polyamine depletion therapy represents a unique cancer immunotherapy approach SEATTLE, June 20, 2018 /PRNewswire/ — Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today announced it received clearance from the Food and Drug Administration

Steba Biotech’s TOOKAD® Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 Years

Steba Biotech’s TOOKAD® Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 Years

June 20, 2018 LUXEMBOURG, June 20, 2018 /PRNewswire/ — Steba Biotech, a privately-owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announced that the Journal of Urology has published 4-year follow

Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

June 19, 2018 Provides IP protection of TG02 in Europe until 09.12.2033 OSLO, Norway, June 19, 2018 /PRNewswire/ — Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), is a clinical stage company focused on developing and commercializing immune activators to target hard to

University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

June 19, 2018 MU pilots Roche’s cloud-based NAVIFY Tumor Board solution to streamline and standardize data collection and presentation, enabling faster, better collaboration among oncology care teams INDIANAPOLIS and COLUMBIA, Mo., June 19, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

June 19, 2018 BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based

GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests

GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests

June 19, 2018 — Now Offering Both Phenotype and Genotype Testing for Antibiotic Resistance — SAN DIEGO and Irvine, Calif., June 19, 2018 /PRNewswire/ — GenomeDx Biosciences and Pathnostics today announced the launch of the next generation Guidance testing for patients suffering from simple

Kazia Releases Preliminary Cantrixil Phase I Data

Kazia Releases Preliminary Cantrixil Phase I Data

SYDNEY, June 19, 2018 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer. The phase

Robotics: Changing the Face of Drug Discovery – PharmaBoardroom

Robotics: Changing the Face of Drug Discovery – PharmaBoardroom

June 19, 2018 While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind. However, as the technology available becomes more advanced, flexible and affordable, robotics now stands as a pivotal